An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 22 Oct 2018
At a glance
- Drugs Rebastinib (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Endometrial cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Deciphera Pharmaceuticals
- 18 Sep 2018 Status changed from not yet recruiting to recruiting.
- 18 Sep 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 17 Sep 2018 to 26 Sep 2018.
- 17 Sep 2018 Planned number of patients changed from 30 to 100.